Evidence map›Paper›PMID 40476637›Full record

SynthesisJournal of medical virology2025

Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of Symptoms 3 Years Post-SARS-CoV-2 Infection.

Masoud Rahmati, Raphael Udeh, Jiseung Kang, Xenia Dolja-Gore, Mark McEvoy, Abdolreza Kazemi, Pinar Soysal, Lee Smith, Tony Kenna, Guillaume Fond and 7 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Masoud RahmatiCEReSS-Health Service Research and Quality of Life Center, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France.ORCID 0000-0003-4792-027X
Raphael UdehSchool of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, New South Wales, Australia.ORCID 0000-0002-9476-6677
Jiseung KangSchool of Health and Environmental Science, Korea University College of Health Science, Seoul, South Korea.ORCID 0000-0002-3734-7572
Xenia Dolja-GoreSchool of Medicine and Public Health, University of Newcastle, NSW, Australia.
Mark McEvoySchool of Medicine and Public Health, University of Newcastle, NSW, Australia.
Abdolreza KazemiCRSMP, Center for Mental Health and Psychiatry Research - PACA, Marseille, France.
Pinar SoysalDepartment of Geriatric Medicine, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Lee SmithCentre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.
Tony KennaCentre for Immunology & Infection Control, Queensland University of Technology, Brisbane, Queensland, Australia.
Guillaume FondCEReSS-Health Service Research and Quality of Life Center, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France.
Bastien BoussatTIMC-IMAG, UMR 5525 Joint Research Unit, Centre National de Recherche Scientifique, National Center for Scientific Research, Université Grenoble-Alpes, Grenoble, France.
Duy Cao NguyenInstitute for Global Health Innovations, Duy Tan University, Da Nang, Vietnam.
Huyen DoResearch Institute for Advanced Nursing (RIAN), Dong Nai Technology University, Bien Hoa, Vietnam.
Bach X TranFaculty of Public Health, VNU University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam.
Nicola VeroneseSaint Camillus International University of Health Sciences, Rome, Italy.ORCID 0000-0002-9328-289X
Dong Keon YonCenter for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Korea.ORCID 0000-0003-1628-9948
Laurent BoyerCEReSS-Health Service Research and Quality of Life Center, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France.

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

The symptoms of long COVID are well-documented. However, the long-term effects beyond 2 years remain poorly understood due to a lack of data. This systematic review and meta-analysis examined the prevalence of persistent symptoms in COVID-19 survivors 3 years following initial SARS-CoV-2 infection. PubMed, MEDLINE (Ovid), CENTRAL, Web of Science, Scopus, and Embase were searched from inception of the databases up to July 20, 2024, by two independent researchers for articles reporting on the prevalence of persistent symptoms 3 years' post-infection of people who survived COVID-19 infection. We employed a random-effect model for the pooled analysis, and the meta-analytical effect size was prevalence for the applicable end-points, I

Indexed as

COVID-19DyspneaFatigueHumansPost-Acute COVID-19 SyndromePrevalenceSARS-CoV-2Sleep Wake DisordersSurvivorsCOVID‐19long COVIDmeta‐analysisSARS‐CoV‐2 infection

Identifiers

PMID40476637
PMCPMC12143191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.